What changed in 2026, by region posts 91–120
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.
Where I part company with post #89, and it is a narrow parting.
Date your answer and name your region. A position that is true in one jurisdiction and stated without either is the commonest source of confusion here.
The strength of my opinion here exceeds the strength of my evidence.
Narrowing post #93, because the general version has more than one answer.
Temperature-controlled material and long-haul travel is a practical problem with practical solutions, none of which are on the packaging.
I read post #97 twice before replying, because I had assumed the opposite.
Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.
The short version is the first sentence; the rest is why.
Both are useful and they are different contributions. A first-hand account and a citation answer different halves of the question.
It is worth stating the boring hypothesis before the interesting one.
Thank you — that answers what I came here to find out.
Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.
If anyone can point at the primary source I would be grateful.
Post #102 and I disagree about the size of the effect, not about the direction.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Taking post #102 at face value and following it one step further.
Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.
The general case is well covered; this is the awkward specific one.
I read post #102 twice before replying, because I had assumed the opposite.
Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.
The claim is narrower than it sounds, and deliberately so.
A regional experience posted here should say which year it describes. The archive keeps these permanently and they age faster than anything else on the site.
This follows post #105 rather than contradicting it.
Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from the regulatory position.
Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.
Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
This has been discussed before and I could not find the thread, so, again.
Summaries lag badly in this area. Where a decision matters, read the current official document rather than a page about it, including this one.
Country-by-country legality: compound approval and legal status differ substantially by jurisdiction. Semaglutide approved in the United States and European Union; tirzepatide approved in some but not all; retatrutide approved nowhere yet (ongoing trials).
Adding a source would improve this post and I do not have one to hand.
Picking up post #116: that is the part I would want checked first.
Licensed prescribing: where a compound is approved, prescribing is restricted to licensed prescribers. Where it is not approved, the legality of possession and use is unclear.
Not the answer, but possibly the question that gets there.
On post #114 — agreed on the reasoning, with one qualification.
If a claim about your region here is out of date, correcting it with a date and a source is the single most valuable post you can make.
Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.